ABSTRACT
Osteoblast differentiation is critically reduced in various bone-related pathogenesis, including arthritis and osteoporosis. For future development of effective regenerative therapeutics, herein, we reveal the involved molecular mechanisms of a phytoestrogen, ferutinin-induced initiation of osteoblast differentiation from dental pulp-derived stem cell (DPSC). We demonstrate the significantly increased expression level of a transcription factor, Kruppel-like factor 2 (KLF2) along with autophagy-related molecules in DPSCs after induction with ferutinin. The loss-of-function and the gain-of-function approaches of KLF2 confirmed that the ferutinin-induced KLF2 modulated autophagic and OB differentiation-related molecules. Further, knockdown of the autophagic molecule (ATG7 or BECN1) from DPSC resulted not only in a decreased level of KLF2 but also in the reduced levels of OB differentiation-related molecules. Moreover, mitochondrial membrane potential-related molecules were increased and induction of mitophagy was observed in DPSCs after the addition of ferutinin. The reduction of mitochondrial as well as total ROS generations; and induction of intracellular Ca2+ production were also observed in ferutinin-treated DPSCs. To test the mitochondrial respiration in DPSCs, we found that the cells treated with ferutinin showed a reduced extracellular acidification rate (ECAR) than that of their vehicle-treated counterparts. Furthermore, mechanistically, chromatin immunoprecipitation (ChIP) analysis revealed that the addition of ferutinin in DPSCs not only induced the level of KLF2, but also induced the transcriptionally active epigenetic marks (H3K27Ac and H3K4me3) on the promoter region of the autophagic molecule ATG7. These results provide strong evidence that ferutinin stimulates OB differentiation via induction of KLF2-mediated autophagy/mitophagy.
Subject(s)
Cycloheptanes , Mitophagy , Autophagy/genetics , Benzoates , Bridged Bicyclo Compounds , Cell Differentiation/genetics , Cells, Cultured , Cycloheptanes/pharmacology , Osteoblasts , Sesquiterpenes , Transcription Factors/pharmacologyABSTRACT
The ribonucleases H (RNases H) of HIV and hepatitis B virus are type 1 RNases H that are promising drug targets because inhibiting their activity blocks viral replication. Eukaryotic ribonuclease H1 (RNase H1) is an essential protein and a probable off-target enzyme for viral RNase H inhibitors. α-hydroxytropolones (αHTs) are a class of anti-RNase H inhibitors that can inhibit the HIV, hepatitis B virus, and human RNases H1; however, it is unclear how these inhibitors could be developed to distinguish between these enzymes. To accelerate the development of selective RNase H inhibitors, we performed biochemical and kinetic studies on the human enzyme, which was recombinantly expressed in Escherichia coli. Size-exclusion chromatography showed that free RNase H1 is monomeric and forms a 2:1 complex with a substrate of 12 bp. FRET heteroduplex cleavage assays were used to test inhibition of RNase H1 in steady-state kinetics by two structurally diverse αHTs, 110 and 404. We determined that turnover rate was reduced, but inhibition was not competitive with substrate, despite inhibitor binding to the active site. Given the compounds' reversible binding to the active site, we concluded that traditional noncompetitive and mixed inhibition mechanisms are unlikely. Instead, we propose a model in which, by binding to the active site, αHTs stabilize an inactive enzyme-substrate-inhibitor complex. This new model clarifies the mechanism of action of αHTs against RNase H1 and will aid the development of RNase H inhibitors selective for the viral enzymes.
Subject(s)
Cycloheptanes , Protein Binding , Catalytic Domain , Cycloheptanes/metabolism , Cycloheptanes/pharmacology , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Humans , Kinetics , Protein Binding/drug effects , Ribonuclease H/chemistryABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Ferula hermonis is a small shrub renowned for its aphrodisiac abilities. Middle East herbalists have utilized Ferula hermonis seed and root as an aphrodisiac folk medicine to treat women's frigidity and male erectile and sexual dysfunction. AIM OF THE STUDY: Assessment of follicle-stimulating hormone-like (FSH), luteinizing hormone-like (LH), and estrogenic activities of the methanolic extract (ME) of the roots of Ferula hermonis on female reproductive function. MATERIALS AND METHODS: The methanolic extract was prepared from the root of F. hermonis and studied at dose level 6 mg/kg in immature female rats for FSH-like, LH-like, and estrogenic activities. These activities were determined by analyzing gross anatomical features, relative organ weight, and serum level of FSH, LH, progesterone and estrogen hormones, and histopathological characteristics. Quantification of the main phytoestrogenic component ferutinin carried out by HPLC. In addition, molecular docking for the binding affinity of ferutinin inside active sites of both estrogen receptor alpha (ERα) and FSH receptor (FSHR) was performed to predict the potential role of ferutinin in regulating the female reproductive process. RESULTS: Ferula hermonis (ME) showed potent FSH-like, LH-like activities and moderate estrogenic effect at the dose of 6 mg/kg. The content of ferutinin in F. hermonis was estimated to be 92 ± 1.33 mg/g of the methanolic extract. Molecular docking of ferutinin with ERα and FSHR displayed strong interaction with target proteins. CONCLUSIONS: Based on results, it can be concluded that Ferula hermonis can be considered as a suitable female fertility improving agent.
Subject(s)
Benzoates/pharmacology , Cycloheptanes/pharmacology , Fertility Agents/pharmacology , Ferula/chemistry , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Animals , Benzoates/isolation & purification , Bridged Bicyclo Compounds/isolation & purification , Bridged Bicyclo Compounds/pharmacology , Chromatography, High Pressure Liquid , Cycloheptanes/isolation & purification , Female , Fertility , Fertility Agents/isolation & purification , Follicle Stimulating Hormone/metabolism , Luteinizing Hormone/metabolism , Molecular Docking Simulation , Rats , Sesquiterpenes/isolation & purificationABSTRACT
The relationship between TLR4 and inflammation-related diseases has been paid more and more attention. The studies have shown that TLR4/NF-κB signaling pathway plays an important role in the transmission of inflammatory signals. A large number of pro-inflammatory factors, chemokines, adhesion factors, TLR4 and its ligands interact with each other, and jointly promote the development of diseases. In this work, 8 target compounds were synthesized to screen the inhibitory activity of TLR4 in vitro. The results of TLR4 inhibition test in vitro showed that the double-ring conjugated enones had a good inhibitory activity, and the IC50 value of compound 4f was 0.56 ± 0.10 µM, and it was superior to the positive control methotrexate. To further study the anti-inflammatory effect and mechanism of double-ring conjugated enones by using LPS induced rat synovial cell inflammation model. The results of the mechanism test showed that compound 4f could effectively promote the apoptosis of rat synovial cells, and the mechanism might be related to the up-regulation of the expression of apoptosis-related protein Caspase-3. In addition, compound 4f could significantly inhibit the increase of inflammatory factors TNF-α, IL-1ß and IL-6 in rat synovial cells induced by LPS, showing a good anti-inflammatory activity. In the TLR4/NF-κB signaling pathway test of rat synovial cells, compound 4f can effectively regulate the expression levels of TLR4, MyD88, NF-κB and IκB related proteins in TLR4/NF-κB signaling pathway, which may be due to its inhibition of LPS-induced inflammation in rat synovial cells. At the same time, it inhibits the abnormal proliferation of cells and its important mechanism promoted of apoptosis.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Antirheumatic Agents/pharmacology , Cyclohexanones/pharmacology , Toll-Like Receptor 4/antagonists & inhibitors , Animals , Anti-Inflammatory Agents/chemical synthesis , Antirheumatic Agents/chemical synthesis , Apoptosis/drug effects , Arthritis, Rheumatoid/drug therapy , Cycloheptanes/chemical synthesis , Cycloheptanes/pharmacology , Cyclohexanones/chemical synthesis , Rats , Signal Transduction/drug effects , Synovial Fluid/cytologyABSTRACT
In recent decades, interest in natural compounds has increased exponentially due to their numerous beneficial properties in the treatment of various acute and chronic diseases. A group of plant derivatives with great scientific interest is terpenic compounds. Among the plants richest in terpenes, the genus Ferula L. is one of the most representative, and ferutinin, the most common sesquiterpene, is extracted from the leaves, rhizome, and roots of this plant. As reported in the scientific literature, ferutinin possesses antioxidant and anti-inflammatory properties, as well as valuable estrogenic properties. Neurodegenerative and demyelinating diseases are devastating conditions for which a definite cure has not yet been established. The mechanisms involved in these diseases are still poorly understood, and oxidative stress is considered to be both a key modulator and a common denominator. In the proposed experimental system, co-cultured human neurons (SH-SY5Y) and human oligodendrocytes (MO3.13) were treated with the pro-inflammatory agent lipopolysaccharide at a concentration of 1 µg/mL for 24 h or pretreated with ferutinin (33 nM) for 24 h and subsequently exposed to lipopolysaccharide 1 µg/mL for 24 h. Further studies would, however, be needed to establish whether this natural compound can be used as a support strategy in pathologies characterized by progressive inflammation and oxidative stress phenomena.
Subject(s)
Benzoates/pharmacology , Cycloheptanes/pharmacology , Inflammation/drug therapy , Lipopolysaccharides/toxicity , Neurons/drug effects , Oligodendroglia/drug effects , Oxidative Stress , Sesquiterpenes/pharmacology , Bridged Bicyclo Compounds/pharmacology , Cell Line , Coculture Techniques , Escherichia coli , Humans , Inflammation/chemically induced , Neurons/metabolism , Neurons/pathology , Oligodendroglia/metabolism , Oligodendroglia/pathology , Protective Agents/pharmacologyABSTRACT
Opioids are the most effective analgesics, with most clinically available opioids being agonists to the µ-opioid receptor (MOR). The MOR is also responsible for their unwanted effects, including reward and opioid misuse leading to the current public health crisis. The imperative need for safer, non-addictive pain therapies drives the search for novel leads and new treatment strategies. In this study, the recently discovered MOR/nociceptin (NOP) receptor peptide hybrid KGNOP1 (H-Dmt-D-Arg-Aba-ß-Ala-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) was evaluated following subcutaneous administration in mouse models of acute (formalin test) and chronic inflammatory pain (Complete Freund's adjuvant-induced paw hyperalgesia), liabilities of spontaneous locomotion, conditioned place preference, and the withdrawal syndrome. KGNOP1 demonstrated dose-dependent antinociceptive effects in the formalin test, and efficacy in attenuating thermal hyperalgesia with prolonged duration of action. Antinociceptive effects of KGNOP1 were reversed by naltrexone and SB-612111, indicating the involvement of both MOR and NOP receptor agonism. In comparison with morphine, KGNOP1 was more potent and effective in mouse models of inflammatory pain. Unlike morphine, KGNOP1 displayed reduced detrimental liabilities, as no locomotor impairment nor rewarding and withdrawal effects were observed. Docking of KGNOP1 to the MOR and NOP receptors and subsequent 3D interaction pattern analyses provided valuable insights into its binding mode. The mixed MOR/NOP receptor peptide KGNOP1 holds promise in the effort to develop new analgesics for the treatment of various pain states with fewer MOR-mediated side effects, particularly abuse and dependence liabilities.
Subject(s)
Oligopeptides/genetics , Opioid Peptides/chemistry , Receptors, Opioid, mu/metabolism , Acute Pain/drug therapy , Analgesics , Animals , Behavior, Animal , CHO Cells , Cricetinae , Cricetulus , Cycloheptanes/pharmacology , Humans , Hyperalgesia/drug therapy , In Vitro Techniques , Inflammation/drug therapy , Male , Mice , Models, Molecular , Molecular Docking Simulation , Morphine/chemistry , Morphine/pharmacology , Movement/drug effects , Naloxone/pharmacology , Naltrexone/pharmacology , Pain Management , Piperidines/pharmacology , NociceptinABSTRACT
Osteoporosis is a common disease in post-menopausal women. The increased risk of breast cancer and malignancy with hormone replacement, hampers its wide-usage. Phytoestrogens are known to have selective estrogen receptor modulator activity. The present study aims to determine how ferutinin affects unrestricted human Somatic Stem Cells (USSCs) osteogenic differentiation. The effect of ferutinin on USSCs proliferation was assessed by MTT assay while osteogenesis was evaluated using Alkaline Phosphatase Activity (ALP), calcium deposition and Alizarin Red Staining. Quantitative real-time PCR was applied to examine the expression of bone specific genes such as osteocalcin, Runx2, and BMP-2. Ferutinin (5-15 µg/mL) could positively impact on the proliferation of cells in a dose-dependent manner. Also, ALP enzyme activity and calcium deposition were enhanced in the presence of ferutinin. Based on real-time PCR results, ferutinin could increase the expression of bone marker genes. The pattern of ferutinin effect on gene expression is similar to standard synthetic estrogen, 17-ß-estradiol. In the presence of the estrogen activity inhibitor (ICI), the effect of ferutinin on ALP and gene level was diminished. In conclusion, ferutinin may be considered as a potential candidate for the stem cell therapy in osteoporosis.
Subject(s)
Adult Stem Cells/cytology , Benzoates/pharmacology , Cell Differentiation , Cycloheptanes/pharmacology , Fetal Blood/cytology , Gene Expression Regulation/drug effects , Osteogenesis , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Adult Stem Cells/drug effects , Adult Stem Cells/metabolism , Bridged Bicyclo Compounds/pharmacology , Cell Proliferation , Cells, Cultured , Ferula/chemistry , Fetal Blood/drug effects , Fetal Blood/metabolism , Gene Expression Profiling , HumansABSTRACT
This study was performed to evaluate the antioxidant, anticancer, and toxicity properties of ferutinin, a phytoestrogen derived from Ferula species. The human Michigan Cancer Foundation-7 (MCF-7) breast cancer cell line and normal human fibroblast (HDF) were cultured and treated with different ferutinin concentrations. The cell viability was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cell death-defining tests (a comparative real-time polymerase chain reaction [for Bax and Bcl-2 genes], flow cytometry, and acridine orange/propidium iodide cell staining). Moreover, 15 white male balb/c mice were divided into three groups of five (one untreated control group and two groups), which received different doses of ferutinin-supplemented water (500 and 1000 µg/kg mice weight) to check the mice liver and kidney pathomorphological alterations and to determine the antioxidant enzymes' expression profile (superoxide dismutase [SOD], catalase [CAT], and glutathione peroxidase) in the mentioned tissues. Finally, the liver lipid peroxidation of mice was analyzed. The results of MTT and cell death-defining tests indicate the significant reduction in cell viability and induction of apoptotic death in MCF-7 cells (enhanced sub-G1 peaks, Bax overexpression, Bcl-2 downregulation, and increased apoptotic cells). The antioxidant enzymes (SOD and CAT) in the mice liver and kidney cells were found to be upregulated (p < .05) in response to the increasing doses of ferutinin. Besides, the lipid peroxidation of the liver tissue of mice was significantly reduced. According to the results, we suggest that ferutinin has the potential to be served as a selective anticancer compound for breast cancer treatment.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Antioxidants/pharmacology , Benzoates/pharmacology , Breast Neoplasms/drug therapy , Cycloheptanes/pharmacology , Ferula/chemistry , Phytoestrogens/pharmacology , Sesquiterpenes/pharmacology , Animals , Antineoplastic Agents, Phytogenic/chemistry , Antioxidants/chemistry , Benzoates/chemistry , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/pharmacology , Cycloheptanes/chemistry , Drug Screening Assays, Antitumor , Female , Humans , MCF-7 Cells , Male , Mice , Mice, Inbred BALB C , Phytoestrogens/chemistry , Sesquiterpenes/chemistryABSTRACT
The employment studies of natural extracts in the prevention and treatment of several diseases highlighted the role of different species of genus Ferula L., belonging to the Apiaceae family, dicotyledonous plants present in many temperate zones of our planet. Ferula communis L. is the main source of sesquiterpene ferutinin, a bioactive compound studied both in vitro and in vivo, because of different effects, such as phytoestrogenic, antioxidant, anti-inflammatory, but also antiproliferative and cytotoxic activity, performed in a dose-dependent and cell-dependent way. The present review will focus on the molecular mechanisms involved in the different activities of Ferutinin, starting from its antioxidant potential at low doses until its ionophoric property and the subsequent mitochondrial dysfunction induced through administration of high doses, which represent the key point of its anticancer action. Furthermore, we will summarize the data acquired from some experimental studies on different cell types and on several diseases. The results obtained showed an important antioxidant and phytoestrogenic regulation with lack of typical side effects related to estrogenic therapy. The preferential cell death induction for tumor cell lines suggests that ferutinin may have anti-neoplastic properties, and may be used as an antiproliferative and cytotoxic agent in an estrogen dependent and independent manner. Nevertheless, more data are needed to clearly understand the effect of ferutinin in animals before using it as a phytoestrogen or anticancer drug.
Subject(s)
Antineoplastic Agents/pharmacology , Antioxidants/pharmacology , Benzoates/pharmacology , Cycloheptanes/pharmacology , Ferula/chemistry , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/therapeutic use , Antioxidants/chemistry , Antioxidants/therapeutic use , Apoptosis/drug effects , Benzoates/chemistry , Benzoates/therapeutic use , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/pharmacology , Bridged Bicyclo Compounds/therapeutic use , Cell Line, Tumor , Cycloheptanes/chemistry , Cycloheptanes/therapeutic use , Dose-Response Relationship, Drug , Electron Transport/drug effects , Hormone Replacement Therapy , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Nitric Oxide/metabolism , Phytochemicals/chemistry , Phytochemicals/pharmacology , Phytoestrogens/chemistry , Phytoestrogens/pharmacology , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Reactive Oxygen Species/metabolism , Sesquiterpenes/chemistry , Sesquiterpenes/therapeutic useABSTRACT
Aminobenzosuberone-based PfA-M1 inhibitors were explored as novel antimalarial agents against two different Plasmodium falciparum strains. The 4-phenyl derivative 7c exhibited the most encouraging growth inhibitory activity with IC50 values of 6.5-11.2 µM. X-ray crystal structures and early assessment of DMPK/ADME-Tox parameters allowed us to initiate structure-based drug design approach and understand the liabilities (such as potential metabolic and aqueous solubility issues) as well as identify the opportunities for improvement of this aminobenzosuberone series. It also suggested that compound 7c should be regarded as an attractive chemical tool to investigate the different biological roles of this multifunctional PfA-M1 protein.
Subject(s)
Aminopeptidases/antagonists & inhibitors , Anisoles/pharmacology , Antimalarials/pharmacology , Cycloheptanes/pharmacology , Enzyme Inhibitors/pharmacology , Plasmodium falciparum/drug effects , Aminopeptidases/metabolism , Anisoles/chemical synthesis , Anisoles/chemistry , Antimalarials/chemical synthesis , Antimalarials/chemistry , Cycloheptanes/chemical synthesis , Cycloheptanes/chemistry , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Molecular Structure , Parasitic Sensitivity Tests , Plasmodium falciparum/enzymology , Structure-Activity RelationshipABSTRACT
Osteoporosis is a silent systemic disease that causes bone deterioration, and affects over 10 million people in the US alone. This study was undertaken to develop a potential stem cell therapy for osteoporosis. We have isolated and expanded human dental pulp-derived stem cells (DPSCs), characterized them, and confirmed their multipotential differentiation abilities. Stem cells often remain quiescent and require activation to differentiate and function. Herein, we show that ferutinin activates DPSCs by modulating the Wnt/ß-catenin signaling pathway and key osteoblast-secreted proteins osteocalcin and collagen 1A1 both mRNA and protein levels. To confirm that ferutinin modulates the Wnt pathway, we inhibited glycogen synthase kinase 3 (GSK3) and found that protein expression patterns were similar to those found in ferutinin-treated DPSCs. To evaluate the role of ferutinin in epigenetic regulation of canonical Wnt signaling, the pathway molecules Wnt3a and Dvl3 were analyzed using chromatin immunoprecipitation (ChIP)-quantitative PCR approaches. We confirmed that active marks of both H3K9 acetylation and H3K4 trimethylation were significantly enhanced in the promoter sites of the WNT3A and DVL3 genes in DPSCs after addition of ferutinin. These data provide evidence that ferutinin activates and promotes osteogenic differentiation of DPSCs, and could be used as an inducer as a potentially effective stem cell therapy for osteoporosis.
Subject(s)
Benzoates/pharmacology , Cycloheptanes/pharmacology , Dental Pulp/metabolism , Epigenesis, Genetic/drug effects , Osteogenesis/drug effects , Sesquiterpenes/pharmacology , Stem Cells/metabolism , Wnt Signaling Pathway/drug effects , Bridged Bicyclo Compounds/pharmacology , Dental Pulp/cytology , Humans , Stem Cells/cytologyABSTRACT
Ferula hermonis Boiss, is an endemic plant of Lebanon, locally known as "shilsh Elzallouh". It has been extensively used in the traditional medicine as an aphrodisiac and for the treatment of sexual impotence. Crude extracts and isolated compounds of ferula hermonis contain phytoestrogenic substances having a wide spectrum of in vitro and in vivo pharmacological properties including anti-osteoporosis, anti-inflammatory, anti-microbial and anti-fungal, anti-cancer and as sexual activity enhancer. The aim of this mini-review is to highlight the traditional and novel applications of this plant's extracts and its major sesquiterpene ester, ferutinin. The phytochemical constituents and the pharmacological uses of ferula hermonis crude extract and ferutinin specifically will be discussed.
Subject(s)
Benzoates/pharmacology , Cycloheptanes/pharmacology , Ferula/chemistry , Phytoestrogens/pharmacology , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Animals , Benzoates/chemistry , Benzoates/therapeutic use , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/pharmacology , Bridged Bicyclo Compounds/therapeutic use , Cycloheptanes/chemistry , Cycloheptanes/therapeutic use , Esters/chemistry , Humans , Phytochemicals/chemistry , Phytochemicals/pharmacology , Phytochemicals/therapeutic use , Phytoestrogens/chemistry , Phytoestrogens/therapeutic use , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Sesquiterpenes/chemistry , Sesquiterpenes/therapeutic useABSTRACT
BACKGROUND: The nociceptin/orphanin FQ opioid peptide (NOP) receptor and its endogenous ligand N/OFQ have been implicated in the regulation of drug and alcohol use disorders (AUD). In particular, evidence demonstrated that NOP receptor activation blocks reinforcing and motivating effects of alcohol across a range of behavioral measures, including alcohol intake, conditioned place preference, and vulnerability to relapse. METHODS: Here, we show the effects of pharmacological activation and inhibition of NOP receptors on binge-like alcohol consumption, as measured by the "drinking in the dark" (DID) model in C57BL/6J mice. RESULTS: We found that 2 potent and selective NOP agonists AT-202 (0, 0.3, 1, 3 mg/kg) and AT-312 (0, 0.3, 1 mg/kg) did not affect binge alcohol drinking at doses that do not affect locomotor activity. AT-202 also failed to alter DID behavior when administered to mice previously exposed to chronic alcohol treatment with an alcohol-containing liquid diet. Conversely, treatment with either the high affinity NOP receptor antagonist SB-612111 (0, 3, 10, 30 mg/kg) or the selective antagonist LY2817412 (0, 3, 10, 30 mg/kg) decreased binge drinking. SB-612111 was effective at all doses examined, and LY2817412 was effective at 30 mg/kg. Consistently, NOP receptor knockout mice consumed less alcohol compared to wild type. SB-612111 reduced DID and increased sucrose consumption at doses that do not appear to affect locomotor activity. However, the high dose of SB-612111 (30 mg/kg) reduced alcohol intake but failed to inhibit preference in a 2-bottle choice DID model that can assess moderate alcohol intake. CONCLUSIONS: The present results suggest that NOP receptor inhibition rather than activation may represent a valuable approach for treatment of AUD characterized by excessive alcohol consumption such as binge drinking.
Subject(s)
Alcohol Deterrents/therapeutic use , Alcohol Drinking/prevention & control , Narcotic Antagonists/therapeutic use , Receptors, Opioid/drug effects , Alcohol Drinking/genetics , Alcohol Drinking/psychology , Animals , Binge Drinking/drug therapy , Binge Drinking/genetics , Binge Drinking/psychology , Central Nervous System Depressants/blood , Cycloheptanes/pharmacology , Darkness , Dose-Response Relationship, Drug , Ethanol/blood , Indoles/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/drug effects , Piperidines/pharmacology , Receptors, Opioid/agonists , Receptors, Opioid/genetics , Nociceptin ReceptorABSTRACT
4-(Pyrimidin-4-yl)morpholines are privileged pharmacophores for PI3K and PIKKs inhibition by virtue of the morpholine oxygen, both forming the key hydrogen bonding interaction and conveying selectivity over the broader kinome. Key to the morpholine utility as a kinase hinge binder is its ability to adopt a coplanar conformation with an adjacent aromatic core favored by the morpholine nitrogen nonbonding pair of electrons interacting with the electron deficient pyrimidine π-system. Few selective morpholine replacements have been identified to date. Herein we describe the discovery of a potent non-nitrogen containing morpholine isostere with the ability to mimic this conformation and its application in a potent selective dual inhibitor of mTORC1 and mTORC2 (29b).
Subject(s)
Bridged Bicyclo Compounds/chemistry , Cycloheptanes/chemistry , Morpholines/chemistry , Phosphatidylinositol 3-Kinases , Phosphoinositide-3 Kinase Inhibitors/chemistry , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , TOR Serine-Threonine Kinases/antagonists & inhibitors , Bridged Bicyclo Compounds/pharmacology , Cycloheptanes/pharmacology , Drug Discovery/methods , Humans , Morpholines/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Phosphoinositide-3 Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Signal Transduction/physiology , TOR Serine-Threonine Kinases/metabolismABSTRACT
BACKGROUND: The peptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are implicated in the modulation of emotional states. Previous human and rodent findings support NOP antagonists as antidepressants. However, the role played by the N/OFQ-NOP receptor system in resilience to stress is unclear. AIMS: The present study investigated the effects of activation or blockade of NOP receptor signaling before exposure to acute stress. METHODS: The behavioral effects of the administration before stress of the NOP agonists Ro 65-6570 (0.01-1 mg/kg) and MCOPPB (0.1-10 mg/kg), and the NOP antagonist SB-612111 (1-10 mg/kg) were assessed in mice exposed to inescapable electric footshock and forced swim as stressors. The behavioral phenotype of mice lacking the NOP receptor (NOP(-/-)) exposed to inescapable electric footshock was also investigated. RESULTS: The activation of NOP receptor signaling with the agonists increased the percentage of mice developing helpless behavior and facilitated immobile posture. In contrast, the blockade of NOP receptor reduced the acquisition of depressive-like phenotypes, and similar resistance to develop helpless behaviors was observed in NOP(-/-) mice. Under the same stressful conditions, the antidepressant nortriptyline (20 mg/kg) did not change the acquisition of helpless behavior and immobile posture. CONCLUSIONS: These findings support the view that NOP activation during acute stress facilitates the development of depressive-related behaviors, whereas NOP blockade has a protective outcome. This study showed for first time that NOP antagonists are worthy of investigation as preemptive treatments in patients with severe risk factors for depression.
Subject(s)
Opioid Peptides/metabolism , Receptors, Opioid/metabolism , Resilience, Psychological/drug effects , Stress, Psychological/drug therapy , Animals , Behavior, Animal/drug effects , Benzimidazoles/administration & dosage , Benzimidazoles/pharmacology , Cycloheptanes/administration & dosage , Cycloheptanes/pharmacology , Depression/drug therapy , Depression/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Imidazoles/administration & dosage , Imidazoles/pharmacology , Male , Mice , Mice, Knockout , Nortriptyline/pharmacology , Piperidines/administration & dosage , Piperidines/pharmacology , Receptors, Opioid/drug effects , Receptors, Opioid/genetics , Spiro Compounds/administration & dosage , Spiro Compounds/pharmacology , Stress, Psychological/physiopathology , Nociceptin Receptor , NociceptinABSTRACT
There is an urgent need to develop novel drugs for osteoporosis which occurs due to estrogen deficiency. Phytoestrogens derived from medicinal plants would be the best alternative to chemical drugs with harmful side effects. The main purpose of the present study was to investigate the effect of ferutinin compared to 17ß-estradiol (E2) on bone mineralization of zebrafish larvae. Regarding the lack of publications, the histology analysis was performed after exposure to E2 to find effective treatment on bone mineralization of developing zebrafish larvae. Then, the larvae were exposed to four concentrations of ferutinin at three time points to assess the mortality, the expression of some related genes and histology of the ceratohyal and hyomandibular of treated larvae. The RT-PCR result of the treatment groups demonstrated the similar expression pattern in the larvae which were exposed to 1.25 µg/mL of ferutinin and 2 µM of E2 at 2 dpf, which confirmed the result of histology analysis. In addition, RT-qPCR of high concentration of ferutinin and E2 demonstrated that bmp2a/b and esr1 were downregulated and upregulated when the larvae were exposed to 5 µg/mL of ferutinin and 10 µM of E2, respectively.
Subject(s)
Benzoates/pharmacology , Calcification, Physiologic/drug effects , Cycloheptanes/pharmacology , Estradiol/pharmacology , Estrogens/pharmacology , Sesquiterpenes/pharmacology , Animals , Bone Morphogenetic Protein 2/genetics , Bone Morphogenetic Protein 2/metabolism , Bridged Bicyclo Compounds/pharmacology , Estrogen Receptor alpha/genetics , Estrogen Receptor alpha/metabolism , Larva/drug effects , Larva/metabolism , Zebrafish , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolismABSTRACT
In the present study a series of dione-thiophenol conjugates was prepared and evaluated against nasopharyngeal carcinoma (NPC) cells. MTT assay showed that compound 4a reduced proliferation of C666-1 and CNE-1â¯cells to 26 and 24%, respectively at 10⯵mol/l concentration. Flow cytometry revealed that increasing the concentration of compound 4a from 2 to 10⯵mol/l increased the proportion of early apoptotic C666-1â¯cells from 2.76 to 69.43%. A significant (Pâ¯<â¯0.001) decrease in the expression of S100P was caused by compound 4a. In compound 4a treated C666-1â¯cells the expression of RAGE, EGFR, CD44, MMP2 and MMP9 was markedly decreased. In summary, compound 4a inhibits nasopharyngeal cancer cell proliferation and induces apoptosis through down-regulation of S100P. Moreover, compound 4a also decreases MMP-2, MMP-9, EGFR, CD44 and RAGE expression in nasopharyngeal cancer cells. Thus, compound 4a can be investigated further as a drug candidate for the treatment of nasopharyngeal cancer.
Subject(s)
Antineoplastic Agents/pharmacology , Calcium-Binding Proteins/antagonists & inhibitors , Cycloheptanes/pharmacology , Nasopharyngeal Carcinoma/diagnostic imaging , Nasopharyngeal Neoplasms/drug therapy , Thiophenes/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Calcium-Binding Proteins/genetics , Calcium-Binding Proteins/metabolism , Cell Proliferation/drug effects , Cycloheptanes/chemistry , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Drug Screening Assays, Antitumor , Humans , Molecular Structure , Nasopharyngeal Carcinoma/secondary , Nasopharyngeal Neoplasms/secondary , Structure-Activity Relationship , Thiophenes/chemistry , Tumor Cells, CulturedABSTRACT
Aggressive behaviors can be considered symptoms of bipolar disorder, schizophrenia, post-traumatic stress, intermittent explosive, and personality disorders. Nociceptin/orphanin FQ (N/OFQ) is a peptide acting as endogenous ligand of the NOP receptor. Preclinical and clinical findings suggest the NOP receptor as an innovative target for the treatment of psychopathologies, such as anxiety, depression, and drug abuse. This study investigated the effects of NOP ligands and the behavioral phenotype of mice lacking the NOP receptor in an animal model of aggressiveness, the resident-intruder test. Mood stabilizers, such as valproate, lithium, and carbamazepine reduced aggressive behaviors of resident mice, while diazepam was inactive. In contrast, para-chlorophenylalanine (PCPA), an inhibitor of 5-HT synthesis, increased aggressiveness in mice. Similar to PCPA, the treatment with the NOP agonists Ro 65-6570 and AT-090 also increased aggressive behaviors. The systemic administration of the NOP antagonist SB-612111 did not modify the behavior of resident mice, but it prevented the aggressive behavior of Ro 65-6570. NOP receptor knockout mice did not display any behavioral difference compared to wild-type animals in the resident-intruder test. None of the treatments affected non-agonistic behaviors and spontaneous locomotion. In conclusion, NOP receptor agonists increased aggressiveness, while the pharmacological and genetic blockade of NOP receptor signaling did not modify agonistic behaviors. Ultimately, the aggressive profile of action of NOP agonists should be taken into account in the development of innovative psychiatric drugs targeting the NOP receptor.
Subject(s)
Aggression/physiology , Agonistic Behavior/physiology , Receptors, Opioid/physiology , Animals , Anxiety , Bipolar Disorder , Carbamazepine/pharmacology , Cycloheptanes/pharmacology , Depression , Depressive Disorder , Disease Models, Animal , Fenclonine/pharmacology , Lithium/pharmacology , Male , Mice , Mice, Knockout , Opioid Peptides/metabolism , Piperidines/pharmacology , Receptors, Opioid/agonists , Receptors, Opioid/genetics , Valproic Acid/pharmacology , Nociceptin Receptor , NociceptinABSTRACT
Two new monoterpenoid indole alkaloids, alstoscholactine (1) and alstolaxepine (2), were isolated from Alstonia scholaris. Compound 1 represents a rearranged stemmadenine alkaloid with an unprecedented C-6-C-19 connectivity, whereas compound 2 represents a 6,7- seco-angustilobine B-type alkaloid incorporating a rare γ-lactone-bridged oxepane ring system. Their structures and absolute configurations were determined by spectroscopic analyses. Compound 1 was successfully semisynthesized from 19 E-vallesamine. Compound 2 induced marked vasorelaxation in rat isolated aortic rings precontracted with phenylephrine.
Subject(s)
Alstonia/chemistry , Cycloheptanes/pharmacology , Heterocyclic Compounds, 4 or More Rings/pharmacology , Indoles/pharmacology , Lactones/pharmacology , Oxepins/pharmacology , Secologanin Tryptamine Alkaloids/pharmacology , Animals , Aorta/drug effects , Cell Line, Tumor , Crystallography, X-Ray , Cycloheptanes/chemistry , Cycloheptanes/isolation & purification , Dose-Response Relationship, Drug , Heterocyclic Compounds, 4 or More Rings/chemistry , Heterocyclic Compounds, 4 or More Rings/isolation & purification , Humans , Indoles/chemistry , Indoles/isolation & purification , Lactones/chemistry , Lactones/isolation & purification , Male , Models, Molecular , Molecular Conformation , Oxepins/chemistry , Oxepins/isolation & purification , Rats , Secologanin Tryptamine Alkaloids/chemistry , Secologanin Tryptamine Alkaloids/isolation & purification , Structure-Activity RelationshipABSTRACT
A short and efficient route to 4-(4-hydroxyphenyl)cycloheptanemethanol was developed, which resulted in the preparation of a mixture of 4 stereoisomers. The stereoisomers were separated by preparative HPLC, and two of the stereoisomers identified by X-ray crystallography. The stereoisomers, as well as a small family of 4-cycloheptylphenol derivatives, were evaluated as estrogen receptor-beta agonists. The lead compound, 4-(4-hydroxyphenyl)cycloheptanemethanol was selective for activating ER relative to seven other nuclear hormone receptors, with 300-fold selectivity for the ß over α isoform and with EC50 of 30-50â¯nM in cell-based and direct binding assays.